Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
European Journal of Cancer, Volume 42, No. 15, Year 2006
Notification
URL copied to clipboard!
Description
Chemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy frequently receive dose reductions and/or delays to their chemotherapy. This may impact on the success of treatment, particularly when treatment intent is either curative or to prolong survival. The incidence of severe or FN can be reduced by prophylactic treatment with granulocyte-colony stimulating factors (G-CSFs), such as filgrastim, lenograstim or pegfilgrastim. However, the use of G-CSF prophylactic treatment varies widely in clinical practice, both in the timing of therapy and in the patients to whom it is offered. While several academic groups have produced evidence-based clinical practice guidelines in an effort to standardise and optimise the management of FN, there remains a need for generally applicable, European-focused guidelines. To this end, we undertook a systematic literature review and formulated recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. We recommend that patient-related adverse risk factors such as elderly age (≥65 years), be evaluated in the overall assessment of FN risk prior to administering each cycle of chemotherapy. In addition, when using a chemotherapy regimen associated with FN in >20% patients, prophylactic G-CSF is recommended. When using a chemotherapy regimen associated with FN in 10-20% patients, particular attention should be given to patient-related risk factors that may increase the overall risk of FN. In situations where dose-dense or dose-intense chemotherapy strategies have survival benefits, prophylactic G-CSF support is recommended. Similarly, if reductions in chemotherapy dose intensity or density are known to be associated with a poor prognosis, primary G-CSF prophylaxis may be used to maintain chemotherapy. Finally, studies have shown that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications, where indicated. © 2006 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Aapro, Matti S.
Switzerland, Genolier
Clinique de Genolier
Cameron, David A.
United Kingdom, Edinburgh
The University of Edinburgh
Pettengell, Ruth
United Kingdom, London
St George's Hospital
Bohlius, Julia
Germany, Koln
Universität zu Köln
Crawford, Jeffrey C.
United States, Durham
Duke Cancer Institute
Ellis, Michael Edward
United Arab Emirates, Al Ain
United Arab Emirates University
Kearney, Nora
United Kingdom, Stirling
University of Stirling
Lyman, Gary H.
United States, Rochester
University of Rochester School of Medicine and Dentistry
Tjan–Heijnen, Vivianne C.G.
Netherlands, Nijmegen
Radboud Universiteit
Walewski, Jan A.
Poland, Warsaw
Maria Sklodowska-curie National Research Institute of Oncology
Weber, Damien Charles
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Zielinski, Christoph Carl
Austria, Innsbruck
Landeskrankenhaus Innsbruck
Statistics
Citations: 520
Authors: 12
Affiliations: 12
Identifiers
Doi:
10.1016/j.ejca.2006.05.002
ISSN:
09598049
Research Areas
Cancer
Health System And Policy
Study Design
Cohort Study
Study Approach
Systematic review